A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Inclusion Criteria: * Male or female at least 18 years of age at the time of signing the informed consent form. * Provided signed written informed consent. * Capable of compliance with the requirements and restrictions listed in the consent form. * Body weight \>=45 kilogram (kg) and a body mass index (BMI) \>=19 Kilogram per meter squared (kg/m\^2) and \<40 kg/m\^2 (inclusive). * Able to swallow and retain oral medication. * BRAF V600 mutation-positive tumor as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory or equivalent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate baseline organ function defined in study protocol. * Women of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study medication. Exclusion Criteria: * History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score \<=6, and PSA \<10 nanogram per milliliter \[ng/mL\]) requiring no or only anti-hormonal therapy, a…